09/837998
Serial # 7
Search results for
Paper # 6

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

**Search Results -**

| Terms | Documents |
|---|---|
| vaccinia and E3L and 184 | 2 |

**Database:** US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search: vaccinia and E3L and 184 Clear

## Search History

**Today's Date: 10/18/2001**

| DB Name | Query | Hit Count | Set Name |
|---|---|---|---|
| USPT,PGPB,JPAB,EPAB,DWPI,TDBD | vaccinia and E3L and 184 | 2 | L6 |
| USPT,PGPB,JPAB,EPAB,DWPI,TDBD | l2 and vaccine$ | 5 | L5 |
| USPT,PGPB,JPAB,EPAB,DWPI,TDBD | vaccinia and E3L near5 expression near3 vector$ | 0 | L4 |
| USPT,PGPB,JPAB,EPAB,DWPI,TDBD | vaccinia and E3L near5 delet$ near10 expression near3 vector$ | 0 | L3 |
| USPT,PGPB,JPAB,EPAB,DWPI,TDBD | vaccinia and E3L near5 delet$ | 6 | L2 |
| USPT,PGPB,JPAB,EPAB,DWPI,TDBD | vaccinia and E3L | 19 | L1 |

WEST

Generate Collection

**Search Results** - Record(s) 1 through 19 of 19 returned.

☐ 1. Document ID: US 6287570 B1

L1: Entry 1 of 19 File: USPT Sep 11, 2001

US-PAT-NO: 6287570
DOCUMENT-IDENTIFIER: US 6287570 B1

TITLE: Vaccine against swine influenza virus

DATE-ISSUED: September 11, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Foley; Patricia L. | Huxley | IA | 50124 | |

US-CL-CURRENT: 424/199.1; 424/232.1, 424/93.1, 424/93.2, 435/235.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: US 6267965 B1

L1: Entry 2 of 19 File: USPT Jul 31, 2001

US-PAT-NO: 6267965
DOCUMENT-IDENTIFIER: US 6267965 B1

TITLE: Recombinant poxvirus--cytomegalovirus compositions and uses

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Paoletti; Enzo | Delmar | NY | | |
| Pincus; Steven E. | East Greenbush | NY | | |
| Cox; William I. | Troy | NY | | |
| Kauffman; Elizabeth K. | Averill Park | NY | | |

US-CL-CURRENT: 424/199.1; 424/204.1, 424/230.1, 424/232.1, 435/235.1, 435/320.1, 530/300, 530/388.1, 536/23.72

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 3. Document ID: US 6183752 B1

L1: Entry 3 of 19 File: USPT Feb 6, 2001

US-PAT-NO: 6183752
DOCUMENT-IDENTIFIER: US 6183752 B1

TITLE: Restenosis/atherosclerosis diagnosis, prophylaxis and therapy

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Epstein; Stephen E. | Rockville | MD | | |
| Finkel; Toren | Bethesda | MD | | |
| Speir; Edith | Annandale | VA | | |
| Zhou; Yi Fu | Bethesda | MD | | |
| Zhu; Jianhui | Bethesda | MD | | |
| Erdile; Lorne | Loudonville | NY | | |
| Pincus; Steven | East Greenbush | NY | | |

US-CL-CURRENT: 424/199.1; 424/230.1, 424/277.1, 424/93.2, 435/320.1, 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 6156496 A

L1: Entry 4 of 19 File: USPT Dec 5, 2000

US-PAT-NO: 6156496
DOCUMENT-IDENTIFIER: US 6156496 A

TITLE: Method for selective inactivation of viral replication

DATE-ISSUED: December 5, 2000

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Miles; Vincent J. | Chestnut Hill | MA | | |
| Mathews; Michael B. | Montclair | NJ | | |
| Katze; Michael G. | Seattle | WA | | |
| Watson; Julia C. | San Jose | CA | | |
| Witherell; Gary | Orinda | CA | | |

US-CL-CURRENT: 435/5; 435/325, 435/455, 435/6, 435/7.1, 514/44, 536/23.1, 536/24.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 6130066 A

L1: Entry 5 of 19 File: USPT Oct 10, 2000

US-PAT-NO: 6130066
DOCUMENT-IDENTIFIER: US 6130066 A

TITLE: Vectors having enhanced expression and methods of making and uses thereof

DATE-ISSUED: October 10, 2000

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Tartaglia; James | Schenectady | NY | | |
| Cox; William I. | Sand Lake | NY | | |
| Gettig; Russell Robert | Averill Park | NY | | |
| Martinez; Hector | Menands | NY | | |
| Paoletti; Enzo | Delmar | NY | | |
| Pincus; Steven E. | East Greenbush | NY | | |

US-CL-CURRENT: 435/69.1; 435/320.1, 435/91.41, 536/23.72

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 6093700 A

L1: Entry 6 of 19 File: USPT Jul 25, 2000

US-PAT-NO: 6093700
DOCUMENT-IDENTIFIER: US 6093700 A

TITLE: Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Mastrangelo; Michael J. | Jenkintown | PA | | |
| Lattime; Edmund C. | Princeton | NJ | | |
| Berd; David | Wyncote | PA | | |
| Eisenlohr; Laurence C. | Merion | PA | | |

US-CL-CURRENT: 514/44; 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 6030785 A

L1: Entry 7 of 19 File: USPT Feb 29, 2000

US-PAT-NO: 6030785
DOCUMENT-IDENTIFIER: US 6030785 A

TITLE: Screening methods to identify agents that selectively inhibit hepatitis C virus replication

DATE-ISSUED: February 29, 2000

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Katze; Michael G. | Seattle | WA | | |
| Gale, Jr.; Michael J. | Monroe | WA | | |

US-CL-CURRENT: 435/6; 435/254.21, 435/375

Full | Title | Citation | Front | Review | Classification | Date | Reference  KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 6004777 A

L1: Entry 8 of 19 File: USPT Dec 21, 1999

US-PAT-NO: 6004777
DOCUMENT-IDENTIFIER: US 6004777 A

TITLE: Vectors having enhanced expression, and methods of making and uses thereof

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Tartaglia; James | Schenectady | NY | | |
| Jacobs; Bertram L. | Phoenix | AZ | | |
| Goebel; Scott J. | Ballston Spa | NY | | |
| Cox; William I. | Sand Lake | NY | | |
| Gettig; Russell Robert | Averill Park | NY | | |
| Pincus; Steven E. | East Greenbush | NY | | |
| Paoletti; Enzo | Delmar | NY | | |

US-CL-CURRENT: 435/69.1; 435/320.1, 435/91.41, 536/23.1, 536/23.72

Full | Title | Citation | Front | Review | Classification | Date | Reference  KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 5997878 A

L1: Entry 9 of 19 File: USPT Dec 7, 1999

US-PAT-NO: 5997878
DOCUMENT-IDENTIFIER: US 5997878 A

TITLE: Recombinant poxvirus-cytomegalovirus, compositions and uses

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Paoletti; Enzo | Delmar | NY | | |
| Pincus; Steven E. | East Greenbush | NY | | |
| Cox; William I. | Sand Lake | NY | | |
| Kauffman; Elizabeth B. | Averill Park | NY | | |

US-CL-CURRENT: 424/199.1; 424/230.1, 424/232.1, 435/235.1, 435/320.1, 435/69.1, 435/69.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 10. Document ID: US 5990388 A

L1: Entry 10 of 19 File: USPT Nov 23, 1999

US-PAT-NO: 5990388
DOCUMENT-IDENTIFIER: US 5990388 A

TITLE: Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Roth; Don Allen | Laramie | WY | | |
| Langland; Jeffrey Olaf | Laramie | WY | | |

US-CL-CURRENT: 800/301; 435/320.1, 800/280, 800/317.2, 800/317.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 11. Document ID: US 5990091 A

L1: Entry 11 of 19 File: USPT Nov 23, 1999

US-PAT-NO: 5990091
DOCUMENT-IDENTIFIER: US 5990091 A

TITLE: Vectors having enhanced expression, and methods of making and uses thereof

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Tartaglia; James | Schenectady | NY | | |
| Cox; William I. | Sand Lake | NY | | |
| Gettig; Russell Robert | Averill Park | NY | | |
| Martinez; Hector | Menands | NY | | |
| Paoletti; Enzo | Delmar | NY | | |
| Pincus; Steven E. | East Greenbush | NY | | |

US-CL-CURRENT: 514/44; 424/93.2, 435/320.1, 435/69.1, 435/91.4, 435/91.41

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 12. Document ID: US 5942235 A

L1: Entry 12 of 19 File: USPT Aug 24, 1999

US-PAT-NO: 5942235
DOCUMENT-IDENTIFIER: US 5942235 A

TITLE: Recombinant poxvirus compositions and methods of inducing immune responses

DATE-ISSUED: August 24, 1999

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Paoletti; Enzo | Delmar | NY | | |

US-CL-CURRENT: 424/232.1; 424/199.1, 424/93.2, 435/320.1, 435/456

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 13. Document ID: US 5833975 A

L1: Entry 13 of 19 File: USPT Nov 10, 1998

US-PAT-NO: 5833975
DOCUMENT-IDENTIFIER: US 5833975 A

TITLE: Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence

DATE-ISSUED: November 10, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Paoletti; Enzo | Delmar | NY | | |
| Tartaglia; James | Schenectady | NY | | |
| Cox; William I. | Troy | NY | | |

US-CL-CURRENT: 424/93.2; 435/320.1, 435/456, 435/69.3, 435/69.5, 435/69.51, 435/69.52

Full | Title | Citation | Front | Review | Classification | Date | Reference  KWIC | Draw Desc | Image

---

☐ 14. Document ID: US 5795713 A

L1: Entry 14 of 19 File: USPT Aug 18, 1998

US-PAT-NO: 5795713
DOCUMENT-IDENTIFIER: US 5795713 A

TITLE: Methods for identifying inducers and inhibitors of programmed cell death

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Roizman; Bernard | Chicago | IL | | |
| He; Bin | Chicago | IL | | |

US-CL-CURRENT: 435/5; 435/15, 435/21

Full | Title | Citation | Front | Review | Classification | Date | Reference  KWIC | Draw Desc | Image

---

☐ 15. Document ID: US 5738985 A

L1: Entry 15 of 19 File: USPT Apr 14, 1998

US-PAT-NO: 5738985
DOCUMENT-IDENTIFIER: US 5738985 A

TITLE: Method for selective inactivation of viral replication

DATE-ISSUED: April 14, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Miles; Vincent J. | San Ramon | CA | | |
| Mathews; Michael B. | Cold Spring Harbor | NY | | |
| Katze; Michael G. | Seattle | WA | | |

US-CL-CURRENT: 435/5; 435/254.2, 435/6, 435/7.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 16. Document ID: WO 200073487 A1

L1: Entry 16 of 19 File: DWPI Dec 7, 2000

DERWENT-ACC-NO: 2001-041152
DERWENT-WEEK: 200105


TITLE: Vaccinia virus with amino acids deleted from the E3L gene product, which reduces virulence and improves efficacy, useful as a vaccine

INVENTOR: BRANDT, T; JACOBS, B

PRIORITY-DATA: 1999US-0136277 (May 27, 1999)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| WO 200073487 A1 | December 7, 2000 | E | 012 | C12P021/06 |

INT-CL (IPC): C07H 21/02; C07H 21/04; C12N 15/39; C12N 15/64; C12P 21/06

Full | Title | Citation | Front | Review | Classification | Date | Reference | KWIC | Draw Desc | Image

---

☐ 17. Document ID: AU 200042469 A, WO 200062735 A2

L1: Entry 17 of 19 File: DWPI Nov 2, 2000

DERWENT-ACC-NO: 2000-656408
DERWENT-WEEK: 200107


TITLE: Treating neopalsms including cancer and solid tumors in a mammal comprises administering interferon-sensitive, replication-competent clonal RNA or DNA viruses such as paramyxovirus and herpesvirus

INVENTOR: GROENE, W S; LORENCE, R M ; RABIN, H ; ROBERTS, M S ; VON BORSTEL, R W

PRIORITY-DATA: 1999US-0292376 (April 15, 1999)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| AU 200042469 A | November 2, 2000 | | 000 | A61K000/00 |
| WO 200062735 A2 | October 26, 2000 | E | 108 | A61K000/00 |

INT-CL (IPC): A61K 0/00

Full | Title | Citation | Front | Review | Classification | Date | Reference  KWIC | Draw Desc | Image

---

☐ 18. Document ID: WO 9955910 A1

L1: Entry 18 of 19 File: DWPI Nov 4, 1999

DERWENT-ACC-NO: 2000-052813
DERWENT-WEEK: 200004


TITLE: Inducing apoptosis in a target cell useful for treating cancer

INVENTOR: JACOBS, B L

PRIORITY-DATA: 1998US-0082976 (April 24, 1998)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| WO 9955910 A1 | November 4, 1999 | E | 025 | C12Q001/68 |

INT-CL (IPC): A61K 48/00; C07H 21/02; C07H 21/04; C12N 15/85; C12N 15/86; C12Q 1/68

Full | Title | Citation | Front | Review | Classification | Date | Reference  KWIC | Draw Desc | Image

---

☐ 19. Document ID: CN 1281336 A, WO 9918799 A1, AU 9896038 A, EP 1032269 A1, HU 200003911 A2

L1: Entry 19 of 19 File: DWPI Jan 24, 2001

DERWENT-ACC-NO: 1999-277360
DERWENT-WEEK: 200130


TITLE: Treating tumours by infection with interferon-sensitive viruses - effective against large tumours that do not respond to chemotherapy

INVENTOR: GROENE, W S; LORENCE, R M ; RABIN, H ; ROBERTS, M S ; VON BORSTEL, R W

PRIORITY-DATA: 1997US-0948244 (October 9, 1997)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| CN 1281336 A | January 24, 2001 | | 000 | A01N063/00 |
| WO 9918799 A1 | April 22, 1999 | E | 094 | A01N063/00 |
| AU 9896038 A | May 3, 1999 | | 000 | A01N063/00 |
| EP 1032269 A1 | September 6, 2000 | E | 000 | A01N063/00 |
| HU 200003911 A2 | February 28, 2001 | | 000 | A01N063/00 |

INT-CL (IPC): A01N 63/00



Generate Collection

| Terms | Documents |
|---|---|
| vaccinia and E3L | 19 |

Display 100 Documents, starting with Document: 19

**Display Format:** Change Format

HILIGHT set on as ''
**HILIGHT set on as ''**
? begin 5,6,55,154,155,156,312,399,biotech,biosci

```
  Set  Items  Description
      ---  -----  -----------
? s vaccinia and E3L and vaccine?

           61724  VACCINIA
             422  E3L
          594465  VACCINE?
      S1      12  VACCINIA AND E3L AND VACCINE?
? rd s1

...completed examining records
      S2      11  RD S1 (unique items)
? d s2/3/1-11

      Display 2/3/1     (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

  129226634    CA: 129(18)226634d    PATENT
  Viral vectors having enhanced expression, and methods of making and uses
thereof
  INVENTOR(AUTHOR): Tartaglia, James; Cox, William I.; Gettig, Russell R.;
Martinez, Hector; Paoletti, Enzo; Pincus, Steven E.
  LOCATION: USA
  ASSIGNEE: Virogenetics Corp.
  PATENT: PCT International ; WO 9840501 A1  DATE: 19980917
  APPLICATION: WO 98US2669 (19980213) *US 816155 (19970312)
  PAGES: 102 pp.  CODEN: PIXXD2  LANGUAGE: English  CLASS: C12N-015/64A;
C12N-015/67B; C12N-015/86B; A61K-048/00B  DESIGNATED COUNTRIES: AU; CA; JP
  DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE

                                - end of record -
? d s2/9/1-11

      Display 2/9/1     (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

  129226634    CA: 129(18)226634d    PATENT
  Viral vectors having enhanced expression, and methods of making and uses
thereof
  INVENTOR(AUTHOR): Tartaglia, James; Cox, William I.; Gettig, Russell R.;
Martinez, Hector; Paoletti, Enzo; Pincus, Steven E.
  LOCATION: USA
  ASSIGNEE: Virogenetics Corp.
  PATENT: PCT International ; WO 9840501 A1  DATE: 19980917
  APPLICATION: WO 98US2669 (19980213) *US 816155 (19970312)
  PAGES: 102 pp.  CODEN: PIXXD2  LANGUAGE: English  CLASS: C12N-015/64A;
C12N-015/67B; C12N-015/86B; A61K-048/00B  DESIGNATED COUNTRIES: AU; CA; JP
  DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE
  SECTION:
CA203002 Biochemical Genetics
CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY

                                -more-
?
```

Display 2/9/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
CA215XXX Immunochemistry
CA263XXX Pharmaceuticals
IDENTIFIERS: vaccinia poxvirus gene expression vector
DESCRIPTORS:
Canarypox virus...
ALVAC deriv. of; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
A1L; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
A2L; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
A7; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...

-more-

?

Display 2/9/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
D6; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
EBER; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
E3L; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Protein formation factors... Transcription factors...
genes for; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
G8R; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
H4L; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof

-more-

?

Display 2/9/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
Genes(microbial)...
H5R; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
K3L; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Vaccinia virus...
NYVAC deriv. of; viral vaccinia and canarypox vectors having enhanced

expression, and methods of making and uses thereof
Genes(microbial)...
TRBP; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Genes(microbial)...
VAI; viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof
Virus vectors...
vCP1452 and vCP1433; viral vaccinia and canarypox vectors having

-more-

?

Display 2/9/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

enhanced expression, and methods of making and uses thereof
Gene expression... Immunity... Poxviridae... Promoter(genetic element)...
Vaccines...
viral vaccinia and canarypox vectors having enhanced expression, and methods of making and uses thereof

- end of record -

?

Display 2/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci


07097015 Genuine Article#: 123ZJ Number of References: 58
Title: Analysis of genomic rearrangement and subsequent gene deletion of the attenuated Orf virus strain D1701
Author(s): Cottone R; Buttner M; Bauer B; Henkel M; Hettich E; Rziha HJ (REPRINT)
Corporate Source: FED RES CTR VIRUS DIS ANIM,INST VACCINES, PAUL EHRLICH STR 28/D-72076 TUBINGEN//GERMANY/ (REPRINT); FED RES CTR VIRUS DIS ANIM,INST VACCINES/D-72076 TUBINGEN//GERMANY/
Journal: VIRUS RESEARCH, 1998, V56, N1 (JUL), P53-67
ISSN: 0168-1702 Publication date: 19980700
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
Language: English Document Type: ARTICLE
Geographic Location: GERMANY
Subfile: CC LIFE--Current Contents, Life Sciences
Journal Subject Category: VIROLOGY
Abstract: The orf virus (OV) strain D1701 belongs to the genetically

-more-

?

Display 2/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

heterogenous parapoxvirus (PPV) genus of the family Poxviridae. The attenuated OV D1701 has been licensed as a live **vaccine** against contagious ecthyma in sheep. Detailed knowledge on the genetic structure and organization of this PPV **vaccine** strain is an important prerequisite to reveal possible genetic mechanisms of PPV attenuation. The present study demonstrates a genomic map of the approximately 158 kbp DNA of OV D1701 established by hybridization

studies of cloned restriction fragments covering the complete viral genome. The results show an enlargement of the inverted terminal repeats (ITR) to up to 18 kbp due to recombination between nonhomologous sequences during cell culture adaptation. DNA sequencing of the region adjacent to the ITR junction revealed the absence of one open reading frame designated E2L. In contrast to a transposition-deletion variant of the New Zealand OV strain NZ2 (Fleming et al., 1995) the two genes **E3L** (a homologue of dUTPase) and G1L neighbouring E2L are retained in OV D1701. DNA and RNA analyses proved the presence of E2L gene in wild-type OV isolated directly from

-more-

?

Display 2/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

scab material. The data presented indicate that the E2L gene is nonessential for virus replication in vitro and in vivo, and may represent one important viral gene in determining virulence and pathogenesis of OV. 
Descriptors--Author Keywords: parapoxvirus ; attenuated orf virus D1701 ; genomic map ; gene deletion
Identifiers--KeyWord Plus(R): INVERTED TERMINAL REPETITION; RESTRICTION ENDONUCLEASE ANALYSIS; THYMIDINE KINASE GENE; **VACCINIA** VIRUS; RABBIT POXVIRUS; COWPOX VIRUS; MONKEYPOX VIRUS; FOWLPOX VIRUS; DNA-SEQUENCE; HUMAN-CELLS
Cited References:
ARCHARD LC, 1979, V45, P51, J GEN VIROL
ARCHARD LC, 1984, V65, P875, J GEN VIROL
BAROUDY BM, 1982, V28, P315, CELL
BINNS MM, 1988, V69, P1275, J GEN VIROL
BLOOM DC, 1991, V65, P1530, J VIROL
BULLER RML, 1991, V55, P80, MICROBIOL REV

-more-

?

Display 2/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

Cited References:
CHOMCZYNSKI P, 1987, V162, P156, ANAL BIOCHEM
DALLO S, 1987, V159, P408, VIROLOGY
DRILLIEN R, 1981, V111, P488, VIROLOGY
DRILLIEN R, 1987, V160, P203, VIROLOGY
DUMBELL KR, 1980, V286, P29, NATURE
EPOSITO JJ, 1978, V89, P53, VIROLOGY
ESPOSITO JJ, 1981, V109, P231, VIROLOGY
FLEMING SB, 1991, V97, P207, GENE
FLEMING SB, 1995, V76, P2969, J GEN VIROL
FLEMING SB, 1997, V71, P4857, J VIROL
FLEMING SB, 1992, V187, P464, VIROLOGY
FLEMING SB, 1993, V195, P175, VIROLOGY
FRASER KM, 1990, V176, P379, VIROLOGY
GARON CF, 1978, V75, P4863, P NATL ACAD SCI USA
GASSMANN U, 1985, V83, P17, ARCH VIROL
GILLARD S, 1986, V83, P5573, P NATL ACAD SCI USA
GOEBEL SJ, 1990, V179, P247, VIROLOGY

-more-

?

Display 2/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

KOTWAL GJ, 1988, V167, P524, VIROLOGY
KROCZEK RA, 1990, V184, P90, ANAL BIOCHEM
LAI ACK, 1989, V12, P239, VIRUS RES
LAKE JR, 1980, V48, P135, J GEN VIROL
LYTTLE DJ, 1994, V68, P84, J VIROL
MACKETT M, 1979, V45, P683, J GEN VIROL
MAYR A, 1981, V28, P535, ZBL VET MED B
MCGEOCH DJ, 1990, V18, P4105, NUCLEIC ACIDS RES
MERCER AA, 1987, V157, P1, VIROLOGY
MERCER AA, 1989, V172, P665, VIROLOGY
MERCER AA, 1995, V212, P698, VIROLOGY
MERCER AA, 1996, V13, P175, VIRUS GENES
MEYER H, 1991, V72, P1031, J GEN VIROL
MOSS B, 1990, V59, P661, ANNU REV BIOCHEM
MOSS B, 1981, V40, P387, J VIROL
MOYER RW, 1980, V22, P545, CELL
MOYER RW, 1980, V102, P119, VIROLOGY

-more-

?

Display 2/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

PAEZ E, 1985, V82, P3365, P NATL ACAD SCI USA
PANICALI D, 1981, V37, P1000, J VIROL
PERKUS ME, 1990, V179, P276, VIROLOGY
PERKUS ME, 1991, V180, P406, VIROLOGY
PICKUP DJ, 1984, V81, P6817, P NATL ACAD SCI USA
PYLES RB, 1992, V66, P6706, J VIROL
RAFII F, 1985, V84, P283, ARCH VIROL
REED KC, 1985, V13, P7207, NUCLEIC ACIDS RES
ROBINSON AJ, 1982, V71, P43, ARCH VIROL
ROBINSON AJ, 1992, P285, RECOMBINANT POXVIRUS
ROBINSON AJ, 1981, V51, P771, VET B
ROBINSON AJ, 1987, V157, P13, VIROLOGY
SULLIVAN JT, 1995, V9, P277, VIRUS GENES
TURNER PC, 1990, V163, P125, CURR TOP MICROBIOL
WITTEK R, 1980, V21, P277, CELL
WITTEK R, 1977, V23, P669, J VIROL
WITTEK R, 1978, V28, P171, J VIROL

-more-

?

Display 2/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

YUEN L, 1987, V84, P6417, P NATL ACAD SCI USA

- end of record -

?

Display 2/9/3 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

00293382 95102809
Distinct patterns of IFN sensitivity observed in cells infected with **vaccinia** K3Lsup - and E3Lsup - mutant viruses
Beattie E.; Paoletti E.; Tartaglia J.
ADDRESS: J. Tartaglia, Virogenetics Corporation, Rensselaer Technology Park, 465 Jordan Road, Troy, NY 12180, United States
Journal: Virology, 210/2 (254-263), 1995, United States
PUBLICATION DATE: 19950000
CODEN: VIRLA
ISSN: 0042-6822
DOCUMENT TYPE: Article
LANGUAGES: English SUMMARY LANGUAGES: English

Recent results have implicated a role for both the VV K3Lsup - and **E3L**-encoded gene products in conferring VV with an IFN-resistant phenotype (Beattie et al., Virology 183, 419-422, 1991; Beattie et al., J.

-more-

?

Display 2/9/3 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.
Virol. 69, 499-505, 1995). As a means of further establishing the mechanisms by which these functions mediate this process in VV-infected cells, we have further assessed the IFN phenotype in K3Lsup - (vP872) and E3Lsup - (vP1080) virus-infected cells. Biochemical and molecular biological analyses were performed comparing the effects of IFN on wild-type as well as K3Lsup - and E3Lsup - virus-infected cells. Expression analyses of the K3L and **E3L** gene products revealed that both are evidenced in virus-infected cells as early as 0.5 hr postinfection. **E3L** expression, however, appears more prolonged, in that it was detectable between 3 to 4 hr postinfection while K3L was undetectable after 3 hr postinfection. Despite having similar expression profiles at early times postinfection, a pronounced sensitivity of protein synthesis to IFN was observed by 30 min postinfection in VV K3Lsup - virus-infected cells, whereas IFN sensitivity was not observed in VV E3Lsup --infected cells until 2 hr postinfection. Subsequent analyses of the IFN-induced antiviral pathways in VV-infected cells demonstrated that the K3L gene product does not contribute to the previously identified specific kinase inhibitory

-more-

?

Display 2/9/3 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.
factor (SKIF) activity but does reduce the level of phosphorylated eIF-2alpha in VV-infected cells. Interestingly, the IFN-induced 2',5'-oligoadenylate synthetase-mediated antiviral pathway was active in VV K3Lsup --infected cells and not in wild-type virus-infected cells. Collectively these results suggest that the K3Lsup -- and E3Lsup --encoded products abrogate the antiviral effect of IFN at distinct levels.

CLASSIFICATION CODE AND DESCRIPTION:

86.7.4.10 - IMMUNOLOGY AND INFECTIOUS DISEASES / IMMUNITY TO INFECTION / Medical and Veterinary Virology / Animal **vaccines**

- end of record -

?

Display 2/9/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE


11164940 EMBASE No: 2001180941
Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A
He Y.; Tan S.-L.; Tareen S.U.; Vijaysri S.; Langland J.O.; Jacobs B.L.; Katze M.G.
M.G. Katze, Department of Microbiology, Box 358070, University of Washington, Seattle, WA 98195 United States
AUTHOR EMAIL: honey@u.washington.edu
Journal of Virology ( J. VIROL. ) (United States) 2001, 75/11 (5090-5098)
CODEN: JOVIA ISSN: 0022-538X
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 59

The NS5A nonstructural protein of hepatitis C virus (HCV) has been shown

-more-

?

Display 2/9/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

to inhibit the cellular interferon (IFN)-induced protein kinase R (PKR). PKR mediates the host IFN-induced antiviral response at least in part by inhibiting mRNA translation initiation through phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2alpha). We thus examined the effect of NS5A inhibition of PKR on mRNA translation within the context of virus infection by using a recombinant **vaccinia** virus (VV)-based assay. The W **E3L** protein is a potent inhibitor of PKR. Accordingly, infection of IFN-pretreated HeLa S3 cells with an **E3L**-deficient W (VVAE3L) resulted in increased phosphorylation levels of both PKR and eIF2alpha. IFN-pretreated cells infected with VV in which the **E3L** locus was replaced with the NS5A gene (VVNS5A) displayed diminished phosphorylation of PKR and eIF2alpha in a transient manner. We also observed an increase in activation of p38 mitogen-activated protein kinase in IFN-pretreated cells infected with VVDELTAE3L, consistent with reports that p38 lies downstream of the PKR pathway. Furthermore, these cells exhibited increased phosphorylation of the capbinding initiation factor 4E (eIF4E), which is downstream of the p38 pathway. Importantly, these effects

-more-

?

Display 2/9/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

were reduced in cells infected with VVNS5A. NS5A was also found to inhibit activation of the p38-eIF4E pathway in epidermal growth factor-treated

cells stably expressing NS5A. NS5A-induced inhibition of eIF2alpha and eIF4E phosphorylation may exert counteracting effects on mRNA translation. Indeed, IFN-pretreated cells infected with VVNS5A exhibited a partial and transient restoration of cellular and viral mRNA translation compared with IFN-pretreated cells infected with VVDELTAE3L. Taken together, these results support the role of NS5A as a PKR inhibitor and suggest a potential mechanism by which HCV might maintain global mRNA translation rate during early virus infection while favoring cap-independent translation of HCV mRNA during late infection.

DRUG DESCRIPTORS:
*messenger RNA--endogenous compound--ec; *virus RNA--endogenous compound --ec; *virus protein--endogenous compound--ec
protein kinase--endogenous compound--ec; **vaccinia vaccine;**
interferon; alpha2 interferon--endogenous compound--ec; mitogen activated

-more-

?

Display 2/9/4 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

protein kinase--endogenous compound--ec; synaptophysin--endogenous compound --ec; initiation factor 4E--endogenous compound--ec; epidermal growth factor; unclassified drug
MEDICAL DESCRIPTORS:
*RNA translation; *Hepatitis C virus
virus infection; HeLa cell; protein phosphorylation; virus gene; signal transduction; cell communication; human; nonhuman; human cell; article; priority journal
DRUG TERMS (UNCONTROLLED): protein kinase r--endogenous compound--ec
CAS REGISTRY NO.: 9026-43-1 (protein kinase); 142243-02-5 (mitogen activated protein kinase); 62229-50-9 (epidermal growth factor)
SECTION HEADINGS:
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology

- end of record -

?

Display 2/9/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE


06215373 EMBASE No: 1995254229
A pilot study demonstrating the feasibility of using intratumoral **vaccinia** injections as a vector for gene transfer
Mastrangelo M.J.; Maguire Jr. H.C.; McCue P.; Lee S.S.; Alexander A.; Nazarian L.N.; Eisenlohr L.C.; Nathan F.; Berd D.; Lattime E.C.
Department of Medicine, Jefferson Medical College, 1015 Walnut Street,Philadelphia, PA 19107 United States
Vaccine Research ( VACCINE RES. ) (United States) 1995, 4/2 (55-69)
CODEN: VAREE ISSN: 1056-7909
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

It has been hypothesized that the acquisition of tumor-specific immunity can be enhanced by enrichment of the cytokine milieu at the site of immunization. As a prelude to exploring the utility of intratumoral injection of **vaccinia** virus recombinants as in vivo insertion vectors

-more-

?

Display 2/9/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.
for cytokine genes, we first demonstrated that three human melanoma cell lines could be infected in vitro with successful expression of the reporter gene product (influenza nuclear protein). In a subsequent pilot study, five patients with dermal, subcutaneous and/or lymph node metastases from cutaneous melanoma were revaccinated with wild-type **vaccinia** virus and, 4 days later, twice weekly intratumoral injections of the same virus were begun. Escalating doses of up to 10sup 7 pock-forming units (PFU) were safely administered repeatedly with modest local (erythema and induration) and mild systemic (flu-like symptoms) reactions. Four of five patients developed antivaccinia virus antibody titers >= 1/3200. With rising antibody titers, local and systemic reactions waned. One patient with a large exophytic lesion experienced dramatic tumor regression with multiple injections of 10sup 7 PFU of virus. Most importantly sequential biopsies of this lesion over a 2-month period demonstrated repeated infection with successful production of viral gene protein (**E3L**) despite antiviral antibody titers as high as 1/12,800. These data demonstrate that **vaccinia** virus can be safely administered repeatedly intralesionally

-more-

?

Display 2/9/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.
and that viral gene function can be maintained for a protracted period even in the face of substantial antiviral antibody titers. We hypothesize that a passenger cytokine gene would function similarly and mediate an immunoadjuvant effect.

DRUG DESCRIPTORS:
*tumor **vaccine**--adverse drug reaction--ae; *tumor **vaccine**--drug therapy--dt; *tumor **vaccine**--clinical trial--ct
carmustine--drug therapy--dt; carmustine--drug combination--cb; cisplatin --drug therapy--dt; cisplatin--drug combination--cb; cytokine--endogenous compound--ec; dacarbazine--drug combination--cb; dacarbazine--drug therapy --dt; gene product; immunological adjuvant; tamoxifen--drug combination--cb ; tamoxifen--drug therapy--dt; virus antibody--endogenous compound--ec
MEDICAL DESCRIPTORS:
*gene transfer
adult; aged; antibody titer; article; chill--side effect--si; clinical article; clinical trial; controlled study; erythema--side effect--si;

-more-

?

Display 2/9/5 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.
female; fever--side effect--si; gene insertion; human; human cell; human tissue; immunization; intratumoral drug administration; lymph node metastasis--drug therapy--dt; lymphadenopathy--side effect--si; male; melanoma cell; myalgia--side effect--si; priority journal; pustule--side

effect--si; reporter gene; skin metastasis--drug therapy--dt; skin necrosis --side effect--si; tumor biopsy; tumor immunity; tumor regression; **vaccinia** virus; virus recombinant
CAS REGISTRY NO.: 154-93-8 (carmustine); 15663-27-1, 26035-31-4, 96081-74-2 (cisplatin); 4342-03-4 (dacarbazine); 10540-29-1 (tamoxifen)
SECTION HEADINGS:
013 Dermatology and Venereology
016 Cancer
026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reaction Titles

- end of record -

?

Display 2/9/6 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal


14500075 PASCAL No.: 00-0163154
ETUDE DES PROTEINES DU VIRUS DE LA **VACCINE** QUI SONT SYNTHETISEES AVANT LA REPLICATION DE L'ADN VIRAL DANS LES CELLULES INFECTEES ET QUI SONT ASSOCIEES AUX VIROSOMES
(Study of early proteins associated with virosomes in **vaccinia** virus-infected cells)
MURCIA NICOLAS Adriana; BEAUD Georges, dir
Universite de Compiegne, Compiegne, Francee
Univ.: Universite de Compiegne. Compiegne. FRA Degree: Th. doct.
1999-07; 1999 75 p.
Availability: INIST-T 129678; T99COMP1212 0000; RBCCN-601592101; T99COMP1212 0000
No. of Refs.: 83 ref.
Document Type: T (Thesis) ; M (Monographic)
Country of Publication: France
Language: French Summary Language: French; English

-more-

?

Display 2/9/6 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal

Le virus de la **vaccine** (Poxviridac) se replique dans les cellules de la plupart de mammiferes et presente la particularite (avec tous les poxvirus) de transcrire ses genes, de repliquer son ADN (193 kb) et de s'assembler dans le cytoplasme des cellules infectees. L'ADN viral neosynthetise est associe a des sites granulaires, denses appelees virosomes. Pendant les premieres etapes du cycle viral, pratiquement tout l'ADN est associe a ces complexes et il en est ensuite libere au cours de l'assemblage du virus de la **vaccine**. Dans la premiere partie de ce travail nous avons identifie par spectrometrie de masses trois proteines virales codees par les genes H5R, **E3L** et E5L synthetisees avant la replication de l'ADN viral et qui sont majoritairement associees aux virosomes. Ce travail caracterise la phosphoproteine H5R comme le composant majeur des virosomes. La proteine **E3L** est une proteine inhibitrice de la proteine kinase PKR induite par l'interferon. Le gene E5L est relativement bien conserve entre les differents poxvirus mais il n'est pas essentiel pour le developpement viral sur trois lignees cellulaires. Dans la deuxieme partie, nous avons montre que ces trois proteines virales

-more-

?

Display 2/9/6 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2001 INIST/CNRS. All rts. reserv.

precoces s'associent, dans les cellules infectees en presence d'un inhibiteur de la replication de l'ADN, a des particules sedimentant moins vite que les virions infectieux. La troisieme partie porte sur la proteine kinase BIR qui est synthetisee a l'etape precoce et qui se localise dans les virosomes essentielle pour la replication de l'ADN viral. La proteine kinase BIR phosphoryle les proteines ribosomiques S2 et Sa des cellules infectees. Nous avons exprime de facon transitoire la proteine BIR dans des cellules HeLa et observe les effets de l'expression de cette proteine sur l'expression d'un gene rapporteur.

English Descriptors: **Vaccinia** virus; Protein; Early; Characterization ; Molecular weight determination; Infected cell; Molecular association
Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus

French Descriptors: Virus **vaccine**; Proteine; Precoce; Caracterisation

-more-

?

Display 2/9/6 (Item 1 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2001 INIST/CNRS. All rts. reserv.

; Determination masse moleculaire; Cellule infectee; Association moleculaire; Virosome

Classification Codes: 002A05C03



- end of record -

?

Display 2/9/7 (Item 2 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2001 INIST/CNRS. All rts. reserv.

11165620 PASCAL No.: 93-0674875
Nuclear localization of a double-stranded RNA-binding protein encoded by the **vaccinia** virus **E3L** gene
HAO YUWEN; COX J H; YEWDELL J W; BENNINK J R; MOSS B
NIH, national inst. allergy infectious diseases, lab. viral diseases, Bethesda MD 20892, USA
Journal: Virology : (New York, NY), 1993, 195 (2) 732-744
ISSN: 0042-6822 CODEN: VIRLAX Availability: INIST-7801; 354000035101210440
No. of Refs.: 1 p.
Document Type: P (Serial) ; A (Analytic)
Country of Publication: USA
Language: English

We produced a B cell hybridoma (TW2.3) from **vaccinia** virus-infected mice that secreted a monoclonal antibody (MAb) reactive with a 25-kDA early viral protein that was localized by laser scanning confocal microscopy to

-more-

?

Display 2/9/7 (Item 2 from file: 144)
DIALOG(R)File 144:Pascal

the nucleus and cytoplasmic viral factory regions of infected cells. By cell-free translation of mRNA selected by hybridization to a complete library of **vaccinia** virus DNA fragments, the immunoreactive polypeptide was mapped to open reading frame **E3L**. The RNA start site of an early promoter was located 26 nucleotides upstream of the first methionine codon of **E3L** . Evidence was obtained that translation initiation occurs in vivo and in vitro at both the first and second methionine codons to produce major and minor polypeptides of 25 and 19 kDa, respectively

English Descriptors: **Vaccinia** virus; Double stranded RNA; Nuclear protein; Localization; Cell nucleus; Infected cell; Cell line; Host virus relation; RNA binding protein
Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus

-more-

?

Display 2/9/7 (Item 2 from file: 144)
DIALOG(R)File 144:Pascal

French Descriptors: Virus **vaccine**; RNA bicatenaire; Proteine nucleaire; Localisation; Noyau cellulaire; Cellule infectee; Lignee cellulaire; Relation hote virus; Gene **E3L**; Proteine liaison RNA

Classification Codes: 002A05C04

- end of record -

?

Display 2/9/8 (Item 3 from file: 144)
DIALOG(R)File 144:Pascal


11069107 PASCAL No.: 93-0576117
Identification of a conserved motif that is necessary for binding of the **vaccinia** virus **E3L** gene products to double-stranded RNA
HWAI-WEN CHANG; JACOBS B L
Arizona State univ., dep. microbiology, molecular cellular biology graduate degree program, Tempe AZ 85287-2701, USA
Journal: Virology : (New York, NY), 1993, 194 (2) 537-547
ISSN: 0042-6822 CODEN: VIRLAX Availability: INIST-7801; 354000033910680110
No. of Refs.: 1 p.
Document Type: P (Serial) ; A (Analytic)
Country of Publication: USA

Language: English
The **E3L** gene of **vaccinia** virus encodes the double-stranded (ds) RNA binding proteins p20 and p25 that exhibit inhibitory activity for the IFN-induced, P SUB 1 /eIF-2 alpha protein kinase. A region in the

-more-

?

Display 2/9/8 (Item 3 from file: 144)
DIALOG(R)File 144:Pascal

**E3L** encoded proteins (residues 156-180) shares a high degree of similarity with several proteins that bind double-helical RNA including the P SUB 1 /eIF-2 alpha kinase, bacterial and yeast RNase III, and a human transactivator response element/Rev response element binding protein. In this study, mutants of **E3L** proteins were constructed in order to determine the region of the proteins required for dsRNA binding and kinase inhibitory activity. Our data indicate that both the region necessary for dsRNA binding and for kinase inhibitory activity are located at the carboxyl terminus of the protein

English Descriptors: **Vaccinia** virus; Proteins; Property structure relationship; C terminal-Sequence; Molecular interaction; Double stranded RNA; Inhibition; Protein kinase
Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzima

-more-

?

Display 2/9/8 (Item 3 from file: 144)
DIALOG(R)File 144:Pascal

French Descriptors: Virus **vaccine**; Proteine; Relation structure propriete; Sequence C terminale; Interaction moleculaire; RNA bicatenaire ; Inhibition; Protein kinase; Proteine EL3

Classification Codes: 002A05C05

- end of record -

?

Display 2/9/9 (Item 4 from file: 144)
DIALOG(R)File 144:Pascal


10932446 PASCAL No.: 93-0441809
The **E3L** and K3L **vaccinia** virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms
DAVIES M V; HWAI-WEN CHANG; JACOBS B L; KAUFMAN R J
Genetics inst., Cambridge MA 02140, USA
Journal: Journal of virology, 1993, 67 (3) 1688-1692
ISSN: 0022-538X Availability: INIST-13592; 354000039238860670
No. of Refs.: 17 ref.
Document Type: P (Serial) ; A (Analytic)
Country of Publication: USA

Language: English
**Vaccinia** virus has evolved multiple mechanisms to counteract the interferon-induced antiviral host cell response. Recently, two **vaccinia** virus gene products were shown to interfere with the activity of the double-stranded RNA-dependent protein kinase (PKR): the K3L

-more-

?

Display 2/9/9 (Item 4 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2001 INIST/CNRS. All rts. reserv.
gene product and the **E3L** gene product. We have evaluated the efficiency by which these gene products inhibit PKR and whether they act in a synergistic manner. The effects of the two **vaccinia** virus gene products were compared in an in vivo system in which translation of a reporter gene (dihydrofolate reductase or eukaryotic translation initiation factor 2 alpha (eIF-2 alpha )) was inhibited because of the localized activation of PKR

English Descriptors: **Vaccinia** virus; Genetical translation; Activation; Mechanism of action; Initiation factor eIF2; Alpha-Peptide chain; Phosphorylation; Synergism; Biological activity
Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzima

French Descriptors: Virus **vaccine**; Traduction genetique; Activation; Mecanisme action; Facteur initiation eIF2; Chaine peptidique alpha ;

-more-

?

Display 2/9/9 (Item 4 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2001 INIST/CNRS. All rts. reserv.
Phosphorylation; Synergie; Activite biologique; Proteine **E3L**; Proteine K3L; Double stranded RNA-dependent protein kinase

Classification Codes: 002A05C05

- end of record -

?

Display 2/9/10 (Item 5 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2001 INIST/CNRS. All rts. reserv.

10222301 PASCAL No.: 92-0428204
The **E3L** gene of **vaccinia** virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase
HWAI-WEN CHANG; WATSON J C; JACOBS B L
Arizona state univ., dep. microbiology, Tempe AZ 48287-2701, USA
Journal: Proceedings of the National Academy of Sciences of the United States of America, 1992, 89 (11) 4825-4829
ISSN: 0027-8424 CODEN: PNASA6 Availability: INIST-574; 354000028272290100
No. of Refs.: 32 ref.

Document Type: P (Serial) ; A (Analytic)
Country of Publication: USA
Language: English
A **vaccinia** virus-encoded double-stranded RNA-binding protein, p25, has been previously implicated in inhibition of the interferon-induced, double-stranded RNA-activated protein kinase. In this study, we have

-more-

?

Display 2/9/10 (Item 5 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2001 INIST/CNRS. All rts. reserv.
identified the **vaccinia** viral gene (WR strain) that encodes p25. Amino acid sequence analysis of a chymotryptic fragment of p25 revealed a close match to the **vaccinia** virus (Copenhagen strain) **E3L** gene. The WR strain **E3L** gene was cloned and expressed either in COS-1 cells or in rabbit reticulocyte lysates in vitro

English Descriptors: Enzyme inhibitor; Gene product; Molecular cloning; Primary structure; **Vaccinia** virus; RNA binding protein
Broad Descriptors: Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzyme; Orthopoxvirus; Chordopoxvirinae; Poxviridae; Virus; Enzima

French Descriptors: Inhibiteur enzyme; Produit gene; Clonage moleculaire; Structure primaire; Virus **vaccine**; Gene **E3L**; Double-stranded RNA-dependent protein kinase; Proteine liaison RNA

-more-

?

Display 2/9/10 (Item 5 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2001 INIST/CNRS. All rts. reserv.
Classification Codes: 002A05C05

- end of record -

?

Display 2/9/11 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2001 Derwent Publ Ltd. All rts. reserv.

0264191 DBA Accession No.: 2001-03945 PATENT
**Vaccinia** virus with amino acids deleted from the **E3L** gene product, which reduces virulence and improves efficacy, useful as a **vaccine** - recombinant **vaccinia** virus and immunization in mouse for **vaccine** and **vaccinia** virus infection therapy
AUTHOR: Jacobs B; Brandt T
CORPORATE SOURCE: Tempe, AZ, USA.
PATENT ASSIGNEE: Univ.Arizona-State 2000
PATENT NUMBER: WO 200073487 PATENT DATE: 20001207 WPI ACCESSION NO.: 2001-041152 (2005)
PRIORITY APPLIC. NO.: US 136277 APPLIC. DATE: 19990527
NATIONAL APPLIC. NO.: WO 2000US10948 APPLIC. DATE: 20000420
LANGUAGE: English
ABSTRACT: **Vaccinia** viruses from which the region encoding at least

amino acids 1-37 of the **E3L** gene product has been deleted, are claimed. Also claimed are: a recombinant **vaccinia** virus

-more-

?

Display 2/9/11 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2001 Derwent Publ Ltd. All rts. reserv.
WR-delta-83N; a composition containing the **vaccinia** virus and a carrier; and a composition containing a recombinant **vaccinia** virus WR-delta-83N and a carrier. A virus (WR, WR-delta-**E3L** or WR-delta-83N) was amplified by infection of RK13 cells until 100% cytopathic effect was observed. Cells were scraped and resuspended in 1 mM Tris, pH 8.8. Amplified viruses were lysed and debris was removed by centrifugation. Supernatant was used for mouse infections. Three to 4 wk old c57b16 mice were anesthetized and mice were subsequently infected with 10 ul of virus or a dilution of virus intranasally in their cages and observed for pathogenesis and death. Intranasal inoculation with WR resulted in death at 10(4) pfu, whereas no pathogenesis could be detected with WR-delta-**E3L** at the highest dose. With WR-delta-83N, 10(7) pfu was required for death, indicating that the N-terminus of **E3L** is an important determinant for virus virulence. The recombinant virus is useful as a **vaccine**. (12pp)
DESCRIPTORS: recombinant **vaccinia** virus, immunization in mouse, appl. recombinant **vaccine**, **vaccinia** virus infection therapy pox

-more-

?

Display 2/9/11 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 2001 Derwent Publ Ltd. All rts. reserv.
virus mammal animal (Vol.20, No.8)
SECTION: PHARMACEUTICALS-**Vaccines**; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology (D4,A1)

- end of display -

?

>>>Page beyond end of display invalid
?
PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES
?